Radiation zaps prostate cancer spots in men not helped enough by hormone drugs
NCT ID NCT07644754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving radiotherapy to the prostate and to cancer spots seen on PET scans can help men with metastatic prostate cancer whose PSA levels remain high after six months of hormone therapy. Participants continue their hormone treatment and receive three PSMA-PET scans along with targeted radiation. The main goal is to see if the cancer stops growing on imaging one year after radiotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiotherapy
What this could lead to
If successful, this approach could offer a way to better control metastatic prostate cancer by targeting both the primary tumor and remaining cancer spots with radiation.
What could go wrong
This is a small, early-phase study with only 27 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue or local irritation, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact